Generate Arrives on Nasdaq Ready To Finally Show the World AI-Powered Medicines

Image: Primary

Published Friday, June 26, 2026 · 8:19 PM EDT

Generate:Biomedicines began trading on the Nasdaq after completing a $425 million initial public offering. CEO Mike Nally rang the opening bell at the exchange in New York on Friday as the generative biology company entered the public markets. Confetti filled the air while company employees and a child held by a parent celebrated the listing. The company said the proceeds will fund two Phase 3 trials of the anti-TSLP antibody GB-0895 in severe asthma. Additional funds will support a Phase 1b trial for a chronic obstructive pulmonary disease therapy and two early-stage cancer assets. Nally told BioSpace that the listing allows the company to show whether artificial intelligence can produce medicines. Nally said generative AI may have its greatest impact in biology and drug discovery. He noted that the time from a 2021 concept to a Phase 3 asset for GB-0895 represents one of the faster timelines in the sector. The company has partnerships with Amgen and Novartis and received backing for the offering from investors that include Novartis, Samsung and NVIDIA. Nally said biotech investors appear willing to support the technology despite questions about the pace of drug development. He added that declining interest rates could support further biotech activity even as markets remain volatile.

Sources

BioSpace

In this story

Nvidia Samsung

Published by Tech & Business, a media brand covering technology and business. This story was sourced from BioSpace and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

Capital Products

U.S. Series A funding reaches $42 billion as deal counts hold steady

U.S. startups raised $42 billion in Series A funding through October 2026, up roughly 60% year over year, while deal counts remained on pace with recent years, Crunchbase data shows.

Products

Ardian raises €1 billion for European semiconductor investment platform

Ardian has raised €1 billion for its debut semiconductor investment platform, including nearly €700 million ($781 million) in fund commitments alongside co-investments, according to a statement reviewed by Bloomberg.

Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

Ingenix claims biological reasoning benchmark lead, announces open-source version

Ingenix says its 9-billion-parameter Thalamus Reasoning model ranks first among 29 models on LongevityBench, which tests language models on cellular aging research.